To therapeutically target CAFs, Geng et al. treated 4T1 breast cancer model mice with an FAPα-targeted DNA vaccine, which led to tumor regression, reduced CAF expression, and diminished secretion of SDF-1 and CCL2 [86,138]. Here, CXCL12 is linked to neoplasm.